Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

This study has been completed.
Information provided by (Responsible Party):
Repros Therapeutics Inc. Identifier:
First received: January 4, 2011
Last updated: June 27, 2014
Last verified: June 2014
The Purpose of the study is to determine the effects of Androxal on morning testosterone and reproductive status in men with secondary hypogonadism(confirmed morning Testosterone less than 250 ng/dL), compared to changes with placebo, or Testim (topical testosterone). The effects of Testim versus placebo on reproductive status will also be examined. Study subjects must not be currently using a topical testosterone.

Condition Intervention Phase
Secondary Hypogonadism
Drug: Placebo
Drug: topical testosterone
Drug: Androxal
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Placebo and Active Controlled, Parallel, Multi-Center Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

Resource links provided by NLM:

Further study details as provided by Repros Therapeutics Inc.:

Primary Outcome Measures:
  • Change in Total Morning Testosterone [ Time Frame: 3 months ]
    Changes in values from baseline in total morning testosterone levels at month 3 comparing Androxal 12.5 and 25 mg to placebo and Testim

Secondary Outcome Measures:
  • Change in Luteinizing Hormone Levels [ Time Frame: 3 months ]
    Changes in values from baseline in LH at month 3

  • Change in FSH After 3 Months of Treatment [ Time Frame: 3 months ]
  • Reproductive Safety [ Time Frame: 3 months ]
    Change from baseline in sperm concentration

Enrollment: 83
Study Start Date: January 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Drug: Placebo
Placebo capsule 1x daily for 3 months
Active Comparator: Testim (topical testosterone)
Testim (topical testosterone)
Drug: topical testosterone
testosterone gel applied 1x daily for 3 months
Other Names:
  • Testim
  • AndroGel
Experimental: Androxal 12.5 mg
Androxal 12.5 mg/day
Drug: Androxal
Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
Other Name: Enclomiphene citrate
Experimental: Androxal 25 mg
Androxal 25 mg/day
Drug: Androxal
Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
Other Name: Enclomiphene citrate

Detailed Description:
This study is a phase IIb, 4 arm study with three month active dosing period. Three of the four treatment groups will be randomized to either Androxal or placebo in a double-blind fashion, and the fourth treatment group will receive open-label Testim. The doses of Androxal in the blinded portion of the study will be 12.5 mg and 25 mg, in capsule form.

Ages Eligible for Study:   21 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Healthy males between the ages of 21 and 65 years of age
  • All clinical laboratory tests within normal ranges (any clinically significant deviation of laboratory results will require approval of sponsor)
  • Previously or concurrently diagnosed as having secondary hypogonadism and confirmed morning testosterone <250ng/dL (two assessments at least 10 days apart)
  • Ability to complete the study in compliance with the protocol
  • Ability to understand and provide written informed consent
  • Agreement to use double barrier contraception if with a fertile female partner
  • Agreement to provide a semen sample in the clinic

Exclusion Criteria:

  • Use of an injectable, oral, topical, or subcutaneous pelleted testosterone within 6 months prior to study
  • Use of spironolactone, cimetidine, Clomid, 5α-reductase inhibitors, hCG, androgen, estrogen, anabolic steroid, DHEA, or herbal hormone products during the study
  • Use of Clomid in the past year
  • Uncontrolled hypertension or diabetes mellitus based on the Investigator's assessment at baseline. Subjects treated for Type II diabetes but exhibiting glycemic control will be allowed into the study
  • A hematocrit >50% or a hemoglobin >17 g/dL
  • Clinically significant abnormal findings on screening examination
  • Use of an investigational drug or product, or participation in a drug or medical device research study within 30 days prior to receiving study medication
  • Known hypersensitivity to Clomid
  • Symptomatic cataracts (nuclear sclerosis cataract or cortical cataract grade > 2 based on 0-4 scale or any trace of posterior subcapsular cataract)
  • Any condition which in the opinion of the investigator would interfere with the participant's ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if he took part in the study
  • Irreversibly infertile or compromised fertility (cryptorchism, Kallman Syndrome, primary hypogonadism, vasectomy, or tumors of the pituitary)
  • Current or history of breast cancer
  • Current or history of prostate cancer or a suspicion of prostate disease unless ruled out by prostate biopsy, or a PSA>3.6
  • Presence or history of hyperprolactinemia with or without a tumor
  • Chronic use of medications use such as glucocorticoids
  • Subjects with cystic fibrosis (mutation of the CFTR gene)
  • Subjects unable to provide a semen sample in the clinic
  • Subject has a BMI >36 kg/m2
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01270841

United States, California
Paradigm Clinical Inc.
Garden Grove, California, United States, 92844
Northern California Research Corp
Sacramento, California, United States, 95831
Medical Center for Clinical Research
San Diego, California, United States, 92108
Los Angeles Biomedical Research Institute
Torrance, California, United States, 90502
United States, Nevada
Affiliated Clinical Research
Las Vegas, Nevada, United States, 89109
Affiliated Clinical Research Inc.
Las Vegas, Nevada, United States, 89144
United States, New York
Weill Cornell Medical College and Smith Institute
Great Neck, New York, United States, 11021
Jed Kaminetsky
New york, New York, United States, 10016
Natan Bar-Chama
New York, New York, United States, 10022
Michael A Werner
Purchase, New York, United States, 10577
United States, Texas
Discovery Clinical Trials
Austin, Texas, United States, 78758
Research Across America
Carrollton, Texas, United States, 75010
Texas Urology Specialist
Houston, Texas, United States, 77024
Centex Research
Houston, Texas, United States, 77062
Endocrine and Psychiatry Center
Houston, Texas, United States, 77095
Protenium Clinical Research
Hurst, Texas, United States, 76054
R/D Clinical Research
Lake Jackson, Texas, United States, 77566
Cetero Research
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Repros Therapeutics Inc.
Principal Investigator: Larry Lipshultz, MD Baylor College of Medicine
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Repros Therapeutics Inc. Identifier: NCT01270841     History of Changes
Other Study ID Numbers: ZA-203
Study First Received: January 4, 2011
Results First Received: June 18, 2014
Last Updated: June 27, 2014

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes
Gonadal Disorders
Endocrine System Diseases
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Estrogen Antagonists
Hormone Antagonists
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents processed this record on April 28, 2017